Overview

The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to explore the effect of increased and decreased urinary pH on the single pharmacokinetic (PK) dose of LY2140023 and its active metabolite LY404039. All participants will receive the three treatments in a randomized order.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company